good Beth. our on Thank investor afternoon, you, joining And quarterly us you call. thank everyone. for Well,
steady the progress the manage our opportunities, of on and our biotherapeutic to to evolve quarters, new our of platform wind we've for of to advance recent made plan testing, COVID-XX In business execution development down linearDNA the applications. revenue
opportunities each within and activities chain calendar our to contribute of our within on to year. our the focus three Now, segments, my our breadth will current ADCL across update supply remarks are business a expected segments fiscal with today revenues prepared and at of that our you on
expect these aggregate, strategic we the revenues referred near-term helping in opportunities entirety. management revenue our facilitate They of in linearDNA costs consequently, that much of the consolidated ongoing burn to. their do are, In can replace however, behind to support Beth these in COVID-XX thereby development operations, us. oriented opportunities with investment not And and our the cash
fiscal long platform, Regarding DNA the customer milestones term in diagnostics cornerstone is for large a which this most to for and quarter. and our a linearDNA announced company's history we growth achieved shipped our shareholders, believe the creation value previously. We produced we the several quarter in
level, production. new production in additional will also basis. this ordered achieve customer a has constructs also higher efficiency to other To biotherapeutic DNA believe that recurring the we we value for products on now This relevant introduced linearDNA methods linearDNA also platform be
grade current large now been previous commercial completely of received of And research receiving names could production from materials quarter. underway for larger marquee received orders order to We into be from orders. customer after industry partially we've in were of biotherapeutic one converting quarters the Now, a IVT repeated and customers fulfillment. our orders scale shipped Three multiple biopharma a second will blossom orders. in for and another fulfilled, were linear the that templates pharma evaluation
give advantage potential offer to some momentarily the am market acquisition rationale messenger I extent believe at RNA use a will we insight I Finally, for IVT into linearDNA that us of the able time, will templates in the production. for this
detailed, later XX. than Beth wind as COVID-XX June Now testing we expect our down largest to contract no
customers whose service also other noted, to operating will COVID-XX our absorb testing continue we she As fully will requirements costs.
challenging future and that CUNY and for safer partners enterprise months. payer team compliment service Now, for strategy I testing that CUNY COVID-XX our for during business saved past I country. And genomic proved works, want the education in model higher ADCL's of lives. time to made the an single their laying we together dedication the our our scale we know testing. extraordinarily XX
learned attractive customer scale service return clear to our or basis at the testing establishes PGx the lessons large pharmacogenomics value customers scale. investment are from that the and to Now to and testing of offers enterprise on economic COVID-XX us a a very development for services
out to service, with will particularly information decisions There for but which There is test. margin provide literature use, self-insured attesting improve on large, for outcomes. patient help Compared inform an price entities. growing Genetic gross powerful and healthcare our and to return testing rationale investment is roll screening per levels, is testing in branded evidence expected can economic lower the PGx with for PGx. higher the and PGx's testing at COVID-XX, a as TRX, extensive
wellbeing When savings and an realize its on large cents while to also population. on the performance dollars increasing care cost, health you of individual benefits enterprise the in and can map substantial PGx populations,
And faster successfully our that targets direct that third-party will differentiated same accounts. is this employ elimination model the ensures within COVID-XX large a model collection. of quite use reimbursement The sales We to customers. enterprise cash large we
Now, a Health package test. we New March its Department assay we're validation our for in of laboratory to and developed PGx State as York review the a submitted awaiting
review category falls for is cycle. two complexity under standard lab, assay permit testing category, quarters the new genetic the PGx Since a clinical our for is high which our to one
one upon at State Health this to barrier us that We their country. will acts a review that entire significant entry a advantage The the make of opportunity the highly as a test approval, time, labs. us. rigorous comprehensive. the as is same and burden for regulatory York bodies many And York Yet of New in Department for greenfield is competitive give believe most such, New high regulatory
the day. higher and partnerships service, discussing capacity per Upon approval XXX testing We're perform to have of our platform over we volumes. tests enhancements PGx to support
an and the We PGx acquisition. positive, with to assay to our lack service very been adopt gates date enterprises likely are feedback engaging has already customer of although testing our approved
clear in which us of market state, in there the and our marketing educator and thought role. puts is from is sales competition little efforts the leadership that in a It way
precision prospective develop to event. of sponsoring our on to key One conference and customers is service testing this medicine, speak fall has and asked our help us their about the
offers the replacement traceability Our also supply chain segment for COVID-XX us opportunity revenues.
and our see customer or with platform for in valuable acquisitions to DNA encompasses isotopic genotyping, UFLPA, multiple other The methods We continue importers Act, due the new testing, testing regulations Labor order other platform. forensic cotton comply tagging of momentum diligence Forced globally. to CertainT authenticity with goods including to CertainT Uyghur that tools, Prevention in are and
Now under UFLPA, Agency platforms isotopic as DNA and reminder, Protection and Border technologies. recognizes two testing for technology a the Customs the compliance
approach the are an offer many integrates the last added UFLPA we've went new effect company June, only for customers. both We source technology verification platforms to that Since into compliance.
advancing we But customers services. even margin are tagging customers we tagging with end, that verification To high a deployment the dollar value DNA customers base source view under conversion compliance revenue. tagging segment would of verification DNA next to our discussions as can result DNA their of higher upsell recurring in whom natural textile increase material the the low a of these Source to in expands who in step rate and UFLPA.
experiencing tagging, are manufacturers. interest We increased especially from DNA apparel in
we've global completed on brand tagged tagging market deliver to testing the to primed chain isotopic chain, Now commercial in anticipate and additional tagging an North follow programs DNA on keep cotton supply underway. apparel the cotton fourth fiscal opportunities This American a chain. Other established actively the the are quarter. initiation first that We initiative of also with to apparel supply flowing. working and an pilot utilized we're its supply
fundamental and are sustainable our Now subsidiary to our and expertise, creation blocks PCR linearDNA our to building we to Applied of the DNA's value growth application story. firmly transitioning LineaRx as biotherapeutics platform committed
advantages genetic RNA biotherapeutic for templates in the manufacturing focus DNA vitro remarkable production. And and The or plasmid platforms. medicines, industry's and Within enzymatic marked other is over that is platform priority our non IVT. based PCR initial has DNA on transcription, DNA
enhance summer, we of raise advantages of linearDNA and therapy ecosystem advance launched our the value to unique templating services developers And service to proposition establish IVT of for to the awareness last with linearDNA's active transition an to our partners, pipelines.
linearDNA Now momentum for IVT building. is for
of we potential flow evaluation mRNA to therapies. additional and for that have marque order creates is feedback larger This and suited received then the very receiving pathways linearDNA. for customers, well manufacture new is demand empower We quantities linearDNA of from the orders are
and we've early these workflows, successes larger manufacturing in under belt, With we recent commercial capabilities on in our focused invested quarters. optimizing our
We in achieved key increases have milestones, including already scale. certain
facility penetration DNA IVT at suitable to or deliver factor to clinical of template GMP is our deeper the for opportunity GMP the for quality. The that is use mRNA need at a gating
phase customers customers, of to and and linearDNA. we the we're clinical from As us expand to our quality linearDNA research higher development This their base capacity orders support generating deliver existing also the building evaluation to value suitable GMP clinic, will capacity allow IVT. for larger for while
to XXXX, manufacturing of over online track about an by to is this capacity are IVT of enough this XXX forecasted doses. And million XX of linearDNA calendar in come to initial with grams the this end you, for template per put for We on capacity year. perspective produce vaccine
linearDNA actively template are to go-to-market matures fully more recruiting IVT for vision share production our partners demand, support who strategy for our As speed we high workflow. clinical enzymatic a
lie Our market and fully generation for IVT the of front sequences the partnering that synthetic across we outperform higher believe, next DNA times. A workflow brand effectively. cost the leading with turnaround workflow, at all synthesis IVT DNA quality while plasmid end relevant make interests can companies new and delivering DNA can quickly metrics, the
for has workflows by for resected today Moderna exciting Now, as patient-specific this or especially just been BioNTech important aggressive for immunotherapies pancreatic individualized demonstrated may be against and view cancers, melanoma, announced cancer. Merck by of the in
are Business at advantages. activities investments throughout coming up our in capabilities, ramping summer be our our with the mRNA will several by development highlighted conferences concurrent showcasing linearDNA's where commercial we presence
I'd more. mRNA represent manufacturing And the a have identified we market. potentially unique cost. RNA chain, of desire X% templates for to the in We've LineaRx that we at of discuss value Finally, looked which the transformative total like frankly, messenger opportunity IVT less than and
identified addressable have of a target moving acquisition gives We the more significant we're increasing potential toward our chain. mRNA value total significantly an us manufacturing that to That's market. access and portion
the linearDNA of the the more that chain. and months makes mRNA compelling impact can or Our case analysis a up several to assets target's combination XX% past the over value
the linearDNA RNA our no IVT advantages But clear, other messenger RNA To desire by to enhance have unique aspects at instead, manufacturing messenger templates currently we be manufacture to of looking of improve scale. we're customers. to
plus unlocking be benefits one opportunity this linearDNA three by RNA supercharges a assets. can our only to several target's is that messenger and the by that our unique feel combination of equals the of We business offering important relating one manufacture our and empowered
with The and the target's commensurate more offer the the to details of on early transaction close value time. current at being in contemplated stage quarter, be we'll that to We hope will have acquisition development.
recap Before some the I've opening to questions, call today. briefly points let key me made
We for are testing COVID-XX revenues. preparing for winddown
next should We have online several developed tagging come at and segment opportunities ADCL in revenue new quarters. that our DNA the
of are offset These revenue testing to COVID opportunities unlikely loss the revenues fully.
be burn. will will help cash at However, our margin, they them and higher manage
balance allows short cash the in us while continuing priorities. to key term increase Our burn absorb cash to execute on
offering is The our This biotherapeutic responding templates. for to IVT gives industry confidence linearDNA very the further resources. DNA to us commit continue well and to
and and believe to moving to to We returns shareholders. deliver toward that our we identified customers acquisition us, have significant an can prospective mRNA are
delivering proud And of of then could be finally, simply more in facets I team growth our across our strategy. not all
we positive that truly capabilities synergistic impact next developed relationships lessons have to comes this we of era our us the with of pandemic has on And our the customers are chapter. appreciative communities. we and our partners. proud the will we the we forward As learned we've armed And to new as a miss move close, are had with
this open my remarks. questions? Operator, call please you Well, the concludes can prepared to
